Caba, BUENOS%20AIRES2 Active Studies

Myalgic Encephalomyelitis Clinical Trials in Caba, BUENOS%20AIRES

Find 2 actively recruiting myalgic encephalomyelitis clinical trials in Caba, BUENOS%20AIRES. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
128
Enrolling

Recruiting Myalgic Encephalomyelitis Studies in Caba

About Myalgic Encephalomyelitis Clinical Trials in Caba

Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.

There are currently 2 myalgic encephalomyelitis clinical trials recruiting participants in Caba, BUENOS%20AIRES. These studies are seeking a combined 128 participants. Research is being sponsored by Novartis Pharmaceuticals, Alexion Pharmaceuticals, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myalgic Encephalomyelitis Clinical Trials in Caba — FAQ

Are there myalgic encephalomyelitis clinical trials in Caba?

Yes, there are 2 myalgic encephalomyelitis clinical trials currently recruiting in Caba, BUENOS%20AIRES. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Caba?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Caba research site will contact you about next steps.

Are clinical trials in Caba free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Caba studies also compensate for your time and travel.

What myalgic encephalomyelitis treatments are being tested?

The 2 active trials in Caba are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.

Data updated March 2, 2026 from ClinicalTrials.gov